Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1351-1360 of 1,873) with videos related to

Pageof 188
Sort By:
American Heart Journal|January 31, 2021
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)Andrew P Ambrosy, Umar I Malik, Rachel C Thomas, et al.
Circulation|September 15, 2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar, Scott D Solomon, Lars Køber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2008
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulatorPeter A Campochiaro, Gulnar Hafiz, Syed Mahmood Shah, et al.
European Journal of Heart Failure|April 17, 2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHEREPooja Dewan, João Pedro Ferreira, Jawad H Butt, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 6, 2026
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical TrialsPablo M Marti-Castellote, Samarra Badrouchi, Brian Claggett, et al.
European Heart Journal|July 2, 2014
Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fractionMauro Gori, Michele Senni, Deepak K Gupta, et al.
European Journal of Heart Failure|February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) ProgrammeAthar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
Nature Genetics|October 7, 2018
Author Correction: Parent-of-origin-specific signatures of de novo mutationsJakob M Goldmann, Wendy S W Wong, Michele Pinelli, et al.
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
Pageof 188

Showing results (1351-1360 of 1,873) with videos related to

Sort By:
Pageof 188
American Heart Journal|January 31, 2021
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)Andrew P Ambrosy, Umar I Malik, Rachel C Thomas, et al.
Circulation|September 15, 2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialDavid Aguilar, Scott D Solomon, Lars Køber, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2008
Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulatorPeter A Campochiaro, Gulnar Hafiz, Syed Mahmood Shah, et al.
European Journal of Heart Failure|April 17, 2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHEREPooja Dewan, João Pedro Ferreira, Jawad H Butt, et al.
JACC. Heart Failure|January 13, 2026
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HFRyohei Ono, Misato Chimura, Kieran F Docherty, et al.
Journal of the American College of Cardiology|January 6, 2026
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical TrialsPablo M Marti-Castellote, Samarra Badrouchi, Brian Claggett, et al.
European Heart Journal|July 2, 2014
Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fractionMauro Gori, Michele Senni, Deepak K Gupta, et al.
European Journal of Heart Failure|February 14, 2015
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) ProgrammeAthar A Badar, Ana C Perez-Moreno, Nathaniel M Hawkins, et al.
Nature Genetics|October 7, 2018
Author Correction: Parent-of-origin-specific signatures of de novo mutationsJakob M Goldmann, Wendy S W Wong, Michele Pinelli, et al.
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
Pageof 188